Hydrophilic or lipophilic statins?

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Climent Biescas, Elisenda
• dc.contributor.author Benaiges Foix, David
• dc.contributor.author Pedro-Botet, Juan Carlos
• dc.date.accessioned 2022-02-09T07:34:46Z
• dc.date.available 2022-02-09T07:34:46Z
• dc.date.issued 2021
• dc.description.abstract Drugs can be classified as hydrophilic or lipophilic depending on their ability to dissolve in water or in lipid-containing media. The predominantly lipophilic statins (simvastatin, fluvastatin, pitavastatin, lovastatin and atorvastatin) can easily enter cells, whereas hydrophilic statins (rosuvastatin and pravastatin) present greater hepatoselectivity. Although the beneficial role of statins in primary and secondary cardiovascular prevention has been unequivocally confirmed, the possible superiority of one statin or other regarding their solubility profile is still not well-established. In this respect, although some previously published observational studies and clinical trials observed a superiority of lipophilic statins in cardiovascular outcomes, these results could also be explained by a greater low-density lipoprotein cholesterol reduction with this statin type. On the other hand, previous studies reported conflicting results as to the possible superiority of one statin type over the other regarding heart failure outcomes. Furthermore, adverse events with statin therapy may also be related to their solubility profile. Thus, the aim of the present review was to collect clinical evidence on possible differences in cardiovascular outcomes among statins when their solubility profile is considered, and how this may also be related to the occurrence of statin-related adverse effects.
• dc.format.mimetype application/pdf
• dc.identifier.citation Climent E, Benaiges D, Pedro-Botet J. Hydrophilic or lipophilic statins? Front Cardiovasc Med. 2021 May 20;8:687585. DOI: 10.3389/fcvm.2021.687585
• dc.identifier.doi http://dx.doi.org/10.3389/fcvm.2021.687585
• dc.identifier.issn 2297-055X
• dc.identifier.uri http://hdl.handle.net/10230/52440
• dc.language.iso eng
• dc.publisher Frontiers
• dc.relation.ispartof Front Cardiovasc Med. 2021 May 20;8:687585
• dc.rights © 2021 Climent, Benaiges and Pedro-Botet. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Adverse effects
• dc.subject.keyword Cardiovascular disease
• dc.subject.keyword Hydrophilic
• dc.subject.keyword Lipophilic
• dc.subject.keyword Pleiotropic effects
• dc.subject.keyword Statins
• dc.title Hydrophilic or lipophilic statins?
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion